Rare Gastrointestinal Diseases Treatment Market Size is valued at USD 1.29 Bn in 2022 and is predicted to reach USD 1.68 Bn by the year 2031 at a 3.1% CAGR during the forecast period for 2023-2031.
Rare gastrointestinal disorders are those that affect the GI (gastrointestinal tract) from the mouth to the anus. Rare gastrointestinal illnesses can be somewhat uncomfortable, severe, or even fatal. Achalasia, celiac disease, Ménétrier disease, Crohn's disease, and gastroesophageal reflux disease are some instances of gastrointestinal illnesses.
Continuous advances in medical research, such as a greater understanding of illness genetic and molecular bases, can lead to the identification of novel therapy targets for uncommon gastrointestinal diseases. These discoveries may pique the interest of both researchers and pharmaceutical corporations in developing tailored medicines. Furthermore, rising government initiatives and spending on gastrointestinal disease treatment are boosting market expansion.
However, the pharmaceutical supply chain experienced disruption, potentially affecting the availability of drugs and treatments for uncommon gastrointestinal disorders during a pandemic. The high costs associated with the research and development of pipeline candidates used for the treatment of rare diseases may stymie market expansion, contributing to the rise in drug prices.
The Rare Gastrointestinal Diseases Treatment Market is segmented on the basis of treatment and end-user. As per the treatment, the market is segmented into medications and nutritional support. The end-user segment includes hospitals, research institutes, and others.
The medications category is expected to hold a major share in the global Rare Gastrointestinal Diseases Treatment Market in 2022. Many rare gastrointestinal disorders qualify for orphan drug classification, which provides pharmaceutical companies with incentives to discover therapies. These advantages include prolonged market exclusivity, tax breaks, and lower regulatory fees, all of which encourage investment in R&D. Because of the tiny patient population for uncommon gastrointestinal disorders, the perceived market size and income potential for drugs can be influenced.
The hospital is projected to grow at a rapid rate in the global Rare Gastrointestinal Diseases Treatment Market. Hospitals frequently collaborate on research projects with academic institutions, pharmaceutical corporations, and patient advocacy organizations. These collaborations propel research and treatment innovation. Advanced diagnostic tools, genetic testing, molecular imaging, and specialized endoscopic methods are frequently available in specialized facilities. Accurate diagnosis is essential for customizing treatment regimens.
The North American rare Gastrointestinal Diseases Treatment Market is expected to record the maximum market share in terms of revenue in the near future. This can be attributed to the increase in patients experiencing uncommon gastrointestinal illnesses. This is due to remarkable lifestyle changes, which have resulted in stomach ulcers, bleeding, haemorrhoids, and anaemia, among other things. Furthermore, government programs aimed at preventing and treating gastrointestinal illnesses are projected to drive the market.
Moreover, Asia Pacific is estimated to grow at a significant rate over the forecast period. The increased recognition of the global market potential for rare illness medicines is prompting pharmaceutical corporations to invest in R&D.
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 1.29 Bn |
|
Revenue Forecast In 2031 |
USD 1.68 Bn |
|
Growth Rate CAGR |
CAGR of 3.1% from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Treatment, End-user |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ; France; Italy; Spain; South Korea; South East Asia |
|
Competitive Landscape |
Bayer Pharmaceutical Corp, Teva Pharmaceutical, Novartis AG, Sanofi, Pfizer, Inc., GlaxoSmithKline PLC, Eli Lilly and CO., Johnson & Johnson, and others. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Rare Gastrointestinal Diseases Treatment Market Snapshot
Chapter 4. Global Rare Gastrointestinal Diseases Treatment Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Treatment Type Estimates & Trend Analysis
5.1. By Treatment Type, & Market Share, 2020 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Treatment Type:
5.2.1. Medications
5.2.2. Nutritional Support
Chapter 6. Market Segmentation 2: By End User Estimates & Trend Analysis
6.1. By End User & Market Share, 2020 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By End User:
6.2.1. Hospitals
6.2.2. Research Institutes
6.2.3. Other End User Settings
Chapter 7. Rare Gastrointestinal Diseases Treatment Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Rare Gastrointestinal Diseases Treatment Market revenue (US$ Million) estimates and forecasts By Treatment Type, 2019-2031
7.1.2. North America Rare Gastrointestinal Diseases Treatment Market revenue (US$ Million) estimates and forecasts By End User, 2019-2031
7.1.3. North America Rare Gastrointestinal Diseases Treatment Market revenue (US$ Million) estimates and forecasts by country, 2019-2031
7.2. Europe
7.2.1. Europe Rare Gastrointestinal Diseases Treatment Market revenue (US$ Million) By Treatment Type, 2019-2031
7.2.2. Europe Rare Gastrointestinal Diseases Treatment Market revenue (US$ Million) By End User, 2019-2031
7.2.3. Europe Rare Gastrointestinal Diseases Treatment Market revenue (US$ Million) by country, 2019-2031
7.3. Asia Pacific
7.3.1. Asia Pacific Rare Gastrointestinal Diseases Treatment Market revenue (US$ Million) By Treatment Type, 2019-2031
7.3.2. Asia Pacific Rare Gastrointestinal Diseases Treatment Market revenue (US$ Million) By End User, 2019-2031
7.3.3. Asia Pacific Rare Gastrointestinal Diseases Treatment Market revenue (US$ Million) by country, 2019-2031
7.4. Latin America
7.4.1. Latin America Rare Gastrointestinal Diseases Treatment Market revenue (US$ Million) By Treatment Type, (US$ Million) 2019-2031
7.4.2. Latin America Rare Gastrointestinal Diseases Treatment Market revenue (US$ Million) By End User, (US$ Million) 2019-2031
7.4.3. Latin America Rare Gastrointestinal Diseases Treatment Market revenue (US$ Million) by country, 2019-2031
7.5. Middle East & Africa
7.5.1. Middle East & Africa Rare Gastrointestinal Diseases Treatment Market revenue (US$ Million) By Treatment Type, (US$ Million) 2019-2031
7.5.2. Middle East & Africa Rare Gastrointestinal Diseases Treatment Market revenue (US$ Million) By End User, (US$ Million) 2019-2031
7.5.3. Middle East & Africa Rare Gastrointestinal Diseases Treatment Market revenue (US$ Million) by country, 2019-2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Bayer Pharmaceutical Corp
8.2.2. Teva Pharmaceutical
8.2.3. Novartis AG
8.2.4. Sanofi
8.2.5. Pfizer, Inc.
8.2.6. GlaxoSmithKline PLC
8.2.7. Eli Lilly and CO.
8.2.8. Johnson & Johnson
Rare Gastrointestinal Diseases Treatment Market By Treatment-
Rare Gastrointestinal Diseases Treatment Market By End-User-
Rare Gastrointestinal Diseases Treatment Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
